Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | Plerixafor + Sargramostim |
| Synonyms | |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Plerixafor | Mozobil | AMD3100 | CXCR4 Inhibitor 15 | Mozobil (plerixafor) inhibits CXCR4 and CXCL12-mediated cell signaling to influence tumor metastasis (PMID: 19641136, PMID: 16815309). |
| Sargramostim | Leukine | GM-CSF|Prokine |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT07605416 | Phase II | Teclistamab Carfilzomib + Daratumumab and hyaluronidase-fihj + Dexamethasone + Lenalidomide Carfilzomib + Lenalidomide Plerixafor + Sargramostim Melphalan | Testing an Experimental Approach to Treat Patients With Plasma Cell Leukemia, The QUANTUM Trial | Recruiting | USA | 0 |